Lorenzo Antonuzzo
Florence, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 274 publications
Predictive biomarkers for cetuximab-based rechallenge therapy in metastatic colorectal cancer: a pooled analysis of the CAVE and CAVE-2 GOIM studies.
Journal: ESMO gastrointestinal oncology
Published: August 28, 2026
Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 28, 2026
Re: Rana R. McKay, Karla V. Ballman, Pamela J. Atherton, et al. Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Renal Cell Carcinoma with Bone Metastases: RADICAL (Alliance A031801). J Clin Oncol. 2026;44:2341-52.
Journal: European urology
Published: August 07, 2026
Design and Synthesis of Bendamustine-Carbonic Anhydrase Inhibitors with Antiproliferative Effects in Clear Cell Renal Cell Carcinoma.
Journal: Journal of medicinal chemistry
Published: June 24, 2026
Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 22, 2026
Beyond prostate-specific antigen: ctDNA as an early compass for treatment adaptation in metastatic prostate cancer.
Journal: Signal transduction and targeted therapy
Published: June 18, 2026
The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026.
Journal: Journal of hematology & oncology
Published: June 04, 2026
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations.
Journal: The New England journal of medicine
Published: May 29, 2026
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations.
Journal: The New England journal of medicine
Published: May 29, 2026
Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort study.
Journal: ESMO gastrointestinal oncology
Published: May 22, 2026
Embarking on a new era in high-risk biochemical recurrent prostate cancer: redefining early systemic intervention.
Journal: Pharmacology & therapeutics
Published: April 28, 2026
Real-world prognostic assessment of the HERO score in metastatic urothelial carcinoma treated with enfortumab vedotin (ARON-2EV study).
Journal: ESMO open
Published: April 21, 2026
Last Updated: 09/26/2026